Updates are available Correction dated 2019-04-24

Article History

Received: 29 September 2017

Accepted: 17 October 2017

First Online: 8 November 2017

Change Date: 24 April 2019

Change Type: Correction

Change Details: The authors would like to note an error in Figures��1 and 2 of this paper. The graph in Figure 1 incorrectly reflected the overall survival (OS), when it should have displayed the progression-free survival (PFS). The caption and median PFS values were correct.

Change Date: 24 April 2019

Change Type: Correction

Change Details: The authors would like to note an error in Figures��1 and 2 of this paper. The graph in Figure 1 incorrectly reflected the overall survival (OS), when it should have displayed the progression-free survival (PFS). The caption and median PFS values were correct.

Compliance with ethical standards

:

: G. Weiss has been a paid consultant for Blend Therapeutics, Pharmatech, IDEA Pharma, AZ Medical Board, GLG Council, Ignyta, Circulogene Theranostics, Viomics, and Paradigm, has received speaker honorarium from Medscape, Merck, Novartis, and Pfizer; holds ownership interest in Circulogene Theranostics, and travel/accommodations from NantWorks, Cambridge Healthtech Institute, and Tesaro. J. Beck, K. Bornemann-Kolatzki, H. Urnovitz, and E. Schütz are employees of and hold ownership interest in Chronix Biomedical. V. Khemka has been a paid consultant for Axcess Oncology. No potential conflicts of interest were disclosed by the other authors.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.